Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis

  • del Monte, Alberto
  • Arroyo, Ana B
  • Andres-Manzano, Maria J.
  • Garcia-Barbera, Nuria
  • Caleprico, Maria S.
  • Vicente, Vicente
  • Roldan, Vanessa
  • Gonzalez-Conejero, Rocio
  • Martinez, Constantino
  • Andres, Vicente
Background Atherosclerosis involves activation of the IRAK1/TRAF6/NF-kappa B inflammatory cascade, which is negatively regulated by miR146a. Previous studies showed that the TT genotype of rs2431697, located near the miR-146a gene, drives lower miR-146a transcription and predicts adverse cardiovascular events in anticoagulated atrial fibrillation patients. Moreover, systemic miR-146a administration protects mice from atherosclerosis. Here we evaluated the ability of miR-146a expression in the hematopoietic component to regulate atherosclerosis in low-density lipoprotein receptor-null mice (LdIr(-/-)). Methods and results Lethally-irradiated LdIr(-/-)mice transplanted with bone marrow from wild-type or miR-146a-null mice were fed an atherogenic diet for 8 and 20 weeks. Irak1, Traf6 and MIR146A expression were quantified in thoracic aorta by qRT-PCR and Western blot. Aortic plaque size and composition were characterized by Oil-Red staining and immunohistochemistry and leukocyte recruitment by intravital microscopy. Blood cell counts were similar in fat-fed Ldir(-/-)mice with or without hematopoietic miR-146a expression. However, plasma cholesterol decreased in fat-fed Ldir(-/-)mice transplanted with bone marrow deficient for miR-146a. Finally, aortic atherosclerosis burden and recruitment of leukocytes into the vessel wall were undistinguishable between the two groups, despite higher levels of Irak1 and Traf6 mRNA and protein in the aorta of fat-fed mice lacking hematopoietic miR-146a expression. Conclusions miR-146a deficiency exclusively in hematopoietic cells modulates cholesterol levels in plasma and the expression of its targets in the artery wall of fat-fed LdIr(-/-)mice, but does not 16 accelerate atherosclerosis. Atheroprotection upon systemic miR-146a administration may therefore be caused by specific effects on vascular cells.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

  • Gorbatenko, Andrej
  • Søkilde, Rolf
  • Sorensen, Ester E.
  • Newie, Inga
  • Persson, Helena
  • Morancho Armisen, Beatriz
  • Arribas López, Joaquin Vicente
Mecanismes de la malaltia; Càncer de mama, Mecanismos de la enfermedad; Cáncer de mama, Disease Mechanisms; Breast Cancer, The HER2 oncogene and its truncated form p95HER2 play central roles in breast cancer. Here, we show that although HER2 and p95HER2 generally elicit qualitatively similar changes in miRNA profile in MCF-7 breast cancer cells, a subset of changes are distinct and p95HER2 shifts the miRNA profile towards the basal breast cancer subtype. High-throughput miRNA profiling was carried out 15, 36 and 60 h after HER2 or p95HER2 expression and central hits validated by RT-qPCR. miRNAs strongly regulated by p95HER2 yet not by HER2, included miR-221, miR-222, miR-503, miR-29a, miR-149, miR-196 and miR-361. Estrogen receptor-α (ESR1) expression was essentially ablated by p95HER2 expression, in a manner recapitulated by miR-221/-222 mimics. c-Myb family transcription factors MYB and MYBL1, but not MYBL2, were downregulated by p95HER2 and by miR-503 or miR-221/-222 mimics. MYBL1 3′UTR inhibition by miR-221/222 was lost by deletion of a single putative miR-221/222 binding sites. p95HER2 expression, or knockdown of either MYB protein, elicited upregulation of tissue inhibitor of matrix metalloprotease-2 (TIMP2). miR-221/222 and -503 mimics increased, and TIMP2 knockdown decreased, cell migration and invasion. A similar pathway was operational in T47D- and SKBr-3 cells. This work reveals important differences between HER2- and p95HER2- mediated miRNA changes in breast cancer cells, provides novel mechanistic insight into regulation of MYB family transcription factors by p95HER2, and points to a role for a miR-221/222– MYB family–TIMP2 axis in regulation of motility in breast cancer cells., This work was supported by the Danish Council for Independent Research (grants no. 12-126942 and 12-127290 to SFP), by the Hartmann foundation (SFP), Fondation Juchum (SFP), Kirsten og Freddy Johansens Fond (SFP), the Breast Cancer Research Foundation (BCRF-17-008) (JA), Instituto de Salud Carlos III (PI16/00253) (JA) and the Harboe foundation (SFP). Katrine Franklin Mark is gratefully acknowledged for excellent technical assistance. We are grateful to Pascal Pineau from Institut Pasteur, France for the MYBL1 3′UTR/psiCHECK2 construct.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

  • Cebrià Costa, Joan Pau
  • Serra Bardenys, Gemma
  • Querol, J
  • Cosín, M
  • Verde, Gaetano
  • Nuciforo, Paolo Giovanni
  • Arribas López, Joaquin Vicente
  • Peiro Sales, Sandra
  • Bernadó Morales, Cristina
  • Pascual Reguant, Laura
  • Gonzalez-Perez, Abel
  • Rodilla Benito, Verónica
Cromosomes; Marcadors pronòstics, Cromosomas; Marcadores de pronóstico, Chromosomes; Prognostic markers, Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenografts (PDXs) than those from other breast cancer subtypes. ChIP-seq revealed that H3K4ox is located primarily in heterochromatin, where it is involved in chromatin compaction. Knocking down LOXL2 reduces H3K4ox levels and causes chromatin decompaction, resulting in a sustained activation of the DNA damage response (DDR) and increased susceptibility to anticancer agents. This critical role that LOXL2 and oxidized H3 play in chromatin compaction and DDR suggests that functionally targeting LOXL2 could be a way to sensitize TNBC cells to conventional therapy., This work was supported by grants from Instituto de Salud Carlos III (ISCIII) FIS/FEDER (PI12/01250; CP08/00223; PI16/00253; and CB16/12/00449), MINECO (SAF2013-48849-C2-1-R) to SP, BFU2015-68354 to THS, Breast Cancer Research Foundation (BCRF-17-008) to JA, AGL2014-52395-C2-2-R to DA, Worldwide Cancer Research, Red Temática de Investigación Cooperativa en Cáncer (RD012/0036/005), Fundación Científica de la Asociación Española contra el Cáncer, and Fundació La Marató TV3. THS was supported by institutional funding (MINECO) through the Centres of Excellence Severo Ochoa award and the CERCA Programme of the Catalan Government, and SS-B, by a Fundació La Caixa fellowship. We thank La Caixa Foundation and Cellex Foundation for provide research facilities and equipment. GV has received funding from the MINECO (a “Juan de la Cierva Incorporation” fellowship; IJCI-2014-20723). SP was a recipient of a Miguel Servet contract (ISCIII/FIS), and AI, JPC-C, LP-G, and GS-B are supported by contracts from Worldwide Cancer Research, Fundació La Marató TV3, Fundació FERO, and a FI Fellowship from the Generalitat de Catalunya, respectively.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Validation of the Spanish version of the borderline symptom list, short form (BSL-23)

  • Soler, Joaquim|||0000-0001-8077-3641
  • Vega, Daniel|||0000-0002-5621-8987
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Trujols, Joan|||0000-0003-0396-7105
  • Soto Lumbreras, Angel
  • Elices, M.|||0000-0002-7034-4242
  • Ortiz, Cristina
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Bohus, Martin
  • Pascual, Juan Carlos|||0000-0001-8039-9346
Background: The Borderline Symptom List-23 (BSL-23) is a reliable and valid self-report instrument for assessing Borderline Personality Disorder (BPD) severity. The psychometric properties of the original version have proven to be adequate. The aim of the present study was to validate the Spanish language version of the BSL-23. Methods: The BSL-23 was administered to 240 subjects with BPD diagnosis. Factor structure, reliability, test-retest stability, convergent validity, and sensitivity to change were analyzed. Results: The Spanish version of the BSL-23 replicates the one-factor structure of the original version. The scale has high reliability (Cronbach's alpha=.949), as well as good test-retest stability, which was checked in a subsample (n=74; r=.734; p<.01). The Spanish BSL-23 shows moderate to high correlations with depressive symptomatology, state and trait anxiety, hostility and impulsivity scores and BPD measures. The Spanish BSL-23 is able to discriminate among different levels of BPD severity and shows satisfactory sensitivity to change after treatment, which was verified by assessing change before and after 12 group sessions of Dialectical Behavioral Therapy in a subgroup of 31 subjects. Conclusions: Similar to the original BSL-23, the Spanish BSL-23 is a reliable and valid instrument for assessing BPD severity and sensitivity to change.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunotherapy with Tolerogenic Dendritic Cells Alone or in Combination with Rapamycin Does Not Reverse Diabetes in NOD Mice

  • Pujol-Autonell, Irma|||0000-0001-6086-4183
  • Ampudia Carrasco, Rosa María|||0000-0002-0734-0433
  • Monge, Pau
  • Lucas Martín, Anna
  • Carrascal, Jorge
  • Verdaguer, Joan
  • Vives Pi, Marta|||0000-0003-3735-0779
Type 1 diabetes is a metabolic disease caused by autoimmunity towards β -cells. Different strategies have been developed to restore β -cell function and to reestablish immune tolerance to prevent and cure the disease. Currently, there is no effective treatment strategy to restore endogenous insulin secretion in patients with type 1 diabetes. This study aims to restore insulin secretion in diabetic mice with experimental antigen-specific immunotherapy alone or in combination with rapamycin, a compound well known for its immunomodulatory effect. Nonobese diabetic (NOD) mice develop spontaneous type 1 diabetes after 12 weeks of age. Autologous tolerogenic dendritic cells-consisting in dendritic cells pulsed with islet apoptotic cells-were administered to diabetic NOD mice alone or in combination with rapamycin. The ability of this therapy to revert type 1 diabetes was determined by assessing the insulitis score and by measuring both blood glucose levels and C-peptide concentration. Our findings indicate that tolerogenic dendritic cells alone or in combination with rapamycin do not ameliorate diabetes in NOD mice. These results suggest that alternative strategies may be considered for the cure of type 1 diabetes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

  • Gorbatenko, A.
  • Søkilde, R.
  • Sorensen, E. E.
  • Newie, I.
  • Persson, H.
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Arribas, Joaquín V|||0000-0002-0504-0664
  • Litman, T.
  • Rovira, Carlos
  • Pedersen, S. F.|||0000-0002-3044-7714
The HER2 oncogene and its truncated form p95HER2 play central roles in breast cancer. Here, we show that although HER2 and p95HER2 generally elicit qualitatively similar changes in miRNA profile in MCF-7 breast cancer cells, a subset of changes are distinct and p95HER2 shifts the miRNA profile towards the basal breast cancer subtype. High-throughput miRNA profiling was carried out 15, 36 and 60 h after HER2 or p95HER2 expression and central hits validated by RT-qPCR. miRNAs strongly regulated by p95HER2 yet not by HER2, included miR-221, miR-222, miR-503, miR-29a, miR-149, miR-196 and miR-361. Estrogen receptor-α (ESR1) expression was essentially ablated by p95HER2 expression, in a manner recapitulated by miR-221/-222 mimics. c-Myb family transcription factors MYB and MYBL1, but not MYBL2, were downregulated by p95HER2 and by miR-503 or miR-221/-222 mimics. MYBL1 3'UTR inhibition by miR-221/222 was lost by deletion of a single putative miR-221/222 binding sites. p95HER2 expression, or knockdown of either MYB protein, elicited upregulation of tissue inhibitor of matrix metalloprotease-2 (TIMP2). miR-221/222 and -503 mimics increased, and TIMP2 knockdown decreased, cell migration and invasion. A similar pathway was operational in T47D- and SKBr-3 cells. This work reveals important differences between HER2- and p95HER2- mediated miRNA changes in breast cancer cells, provides novel mechanistic insight into regulation of MYB family transcription factors by p95HER2, and points to a role for a miR-221/222- MYB family-TIMP2 axis in regulation of motility in breast cancer cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58

  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Serrano, Beatriz
  • Tous, Sara|||0000-0002-5423-7092
  • Alejo, María
  • Lloveras, Belen|||0000-0001-8659-5241
  • Quiros Blasco, Beatriz|||0000-0002-6187-3732
  • Clavero, Omar|||0000-0001-9721-6382
  • Vidal, August|||0000-0001-5727-2099
  • Ferrandiz-Pulido, Carla|||0000-0003-3688-9596
  • Pavón, Miquel Ángel
  • Holzinger, Dana
  • Halec, Gordana
  • Tommasino, Massimo
  • Quint, Wim
  • Pawlita, Michael
  • Muñoz, Nubia
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Alemany, Laia|||0000-0003-0945-6015
Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vaccination programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA-positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16 INK4a immunohistochemistry. For cervical cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16 INK4a biomarkers. The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

  • Cebrià Costa, Joan Pau|||0000-0002-3628-2973
  • Pascual Reguant, Laura|||0000-0003-2361-1392
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Serra-Bardenys, Gemma
  • Querol, Jessica|||0000-0002-0527-759X
  • Cosín Tomás, Marc
  • Verde, Gaetano|||0000-0003-4768-0165
  • Aiese Cigliano, Riccardo|||0000-0002-9058-6994
  • Sanseverino, Walter|||0000-0003-3324-5912
  • Segura-Bayona, Sandra|||0000-0001-7788-9889
  • Iturbide, Ane
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Rodilla, Verónica|||0000-0003-0512-4179
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Yélamos, José|||0000-0003-1195-1496
  • Garcia de Herreros, Antonio|||0000-0001-5270-0808
  • Stracker, Travis H.|||0000-0002-8650-2081
  • Peiró, Sandra|||0000-0001-9519-3877
Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenografts (PDXs) than those from other breast cancer subtypes. ChIP-seq revealed that H3K4ox is located primarily in heterochromatin, where it is involved in chromatin compaction. Knocking down LOXL2 reduces H3K4ox levels and causes chromatin decompaction, resulting in a sustained activation of the DNA damage response (DDR) and increased susceptibility to anticancer agents. This critical role that LOXL2 and oxidized H3 play in chromatin compaction and DDR suggests that functionally targeting LOXL2 could be a way to sensitize TNBC cells to conventional therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells

  • Georgilis, Athena
  • Klotz, Sabrina
  • Hanley, Christopher J.
  • Herranz, Nicolas
  • Weirich, Benedikt
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Leote, Ana Carolina
  • D'Artista, Luana
  • Gallage, Suchira
  • Seehawer, Marco
  • Carroll, Thomas
  • Dharmalingam, Gopuraja
  • Wee, Keng Boon
  • Mellone, Marco
  • Pombo, Joaquim
  • Heide, Danijela
  • Guccione, Ernesto
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Barbosa-Morais, Nuno L.
  • Heikenwälder, Mathias
  • Thomas, Gareth J.
  • Zender, Lars
  • Gil, Jesús
Oncogene-induced senescence is a potent tumor-suppressive response. Paradoxically, senescence also induces an inflammatory secretome that promotes carcinogenesis and age-related pathologies. Consequently, the senescence-associated secretory phenotype (SASP) is a potential therapeutic target. Here, we describe an RNAi screen for SASP regulators. We identified 50 druggable targets whose knockdown suppresses the inflammatory secretome and differentially affects other SASP components. Among the screen candidates was PTBP1. PTBP1 regulates the alternative splicing of genes involved in intracellular trafficking, such as EXOC7, to control the SASP. Inhibition of PTBP1 prevents the pro-tumorigenic effects of the SASP and impairs immune surveillance without increasing the risk of tumorigenesis. In conclusion, our study identifies SASP inhibition as a powerful and safe therapy against inflammation-driven cancer. By performing a genetic screen for regulators of the senescence-associated secretory phenotype (SASP), Georgilis et al. identify PTBP1, which controls SASP by regulating alternative splicing of genes involved in intracellular trafficking such as EXOC7. PTBP1 knockdown blocks the tumor-promoting functions of SASP.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy

  • Floros, Konstantinos V.
  • Lochmann, Timothy L.|||0000-0002-3368-6067
  • Hu, Bin
  • Monterrubio, Carles
  • Hughes, Mark T.
  • Wells, Jason D.
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Ghotra, Maninderjit S.
  • Costa, Carlotta|||0000-0002-1199-2485
  • Souers, Andrew J.
  • Boikos, Sosipatros A.
  • Leverson, Joel D.
  • Tan, Ming
  • Serra, Violeta|||0000-0001-6620-1065
  • Koblinski, Jennifer E.
  • Arribas, Joaquín V|||0000-0002-0504-0664
  • Prat, Aleix|||0000-0003-2377-540X
  • Paré Brunet, Laia
  • Miller, Todd W.
  • Dozmorov, Mikhail G.|||0000-0002-0086-8358
  • Harada, Hisashi
  • Windle, Brad E.
  • Scaltriti, Maurizio|||0000-0002-5522-1447
  • Faber, Anthony C.
In HER2 -amplified breast cancers, HER2 inhibitors have been very successful as adjuvant therapy but not as monotherapy. Here, we demonstrate that coamplification of a HER2 intronic miRNA causes intrinsic resistance to HER2 inhibitors by indirectly down-regulating the pro-apoptotic NOXA. Importantly, coinhibition with MCL-1 inhibitors overcomes this resistance. HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the robust responses to other receptor tyrosine kinase inhibitors like EGFR inhibitors in EGFR -mutant lung cancer. Interestingly, the lack of HER2i efficacy occurs despite sufficient intracellular signaling shutdown following HER2i treatment. Exploring possible intrinsic causes for this lack of response, we uncovered remarkably depressed levels of NOXA, an endogenous inhibitor of the antiapoptotic MCL-1, in HER2 -amplified breast cancer. Upon investigation of the mechanism leading to low NOXA, we identified a micro-RNA encoded in an intron of HER2, termed miR-4728, that targets the mRNA of the Estrogen Receptor α (ESR1). Reduced ESR1 expression in turn prevents ERα-mediated transcription of NOXA, mitigating apoptosis following treatment with the HER2i lapatinib. Importantly, resistance can be overcome with pharmacological inhibition of MCL-1. More generally, while many cancers like EGFR -mutant lung cancer are driven by activated kinases that when drugged lead to robust monotherapeutic responses, we demonstrate that the efficacy of targeted therapies directed against oncogenes active through focal amplification may be mitigated by coamplified genes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Erratum to, Validation of the Spanish version of the borderline symptom list, short form (BSL-23)

  • Soler, Joaquim|||0000-0001-8077-3641
  • Vega, Daniel|||0000-0002-5621-8987
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Trujols, Joan|||0000-0003-0396-7105
  • Soto, Ángel
  • Elices, M.|||0000-0002-7034-4242
  • Ortiz, Cristina
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Bohus, Martin
  • Pascual, Juan Carlos|||0000-0001-8039-9346
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of anandamide and 2-arachidonoylglycerol concentrations with clinical features and body mass index in eating disorders and obesity

  • Baenas Soto, Isabel Maria|||0000-0001-7415-0616
  • Miranda-Olivos, Romina|||0000-0003-2360-5830
  • Granero, Roser|||0000-0001-6308-3198
  • Codina, Ester|||0000-0002-0848-0614
  • Solé-Morata, Neus|||0000-0003-0433-0843
  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Pastor, Antoni|||0000-0003-3692-0696
  • Pino Gutiérrez, Amparo del|||0000-0002-2854-9850
  • Tinahones, Francisco J.|||0000-0001-6871-4403
  • Fernandez Formoso, Jose Antonio|||0000-0001-5310-1655
  • Vilarrasa, Nuria|||0000-0003-3188-1990
  • Guerrero-Pérez, Fernando
  • López-Urdiales, Rafael|||0000-0002-2355-3041
  • Virgili, Nuria
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) play a pivotal role in stimulating motivational behavior toward food and energy metabolism. Aberrant functioning of the endocannabinoid system has been observed in extreme weight conditions (EWCs), suggesting it may influence pathophysiology. Then, we aimed to analyze fasting AEA and 2-AG plasma concentrations among individuals with EWC (i.e., anorexia nervosa [AN] and obesity with and without eating disorders [EDs]) compared with healthy controls (HCs), and its association with clinical variables and body mass index (BMI). The sample included 113 adult women. Fifty-seven belonged to the obesity group, 37 without EDs (OB-ED) and 20 with ED (OB+ED classified within the binge spectrum disorders), 27 individuals from the AN group, and 29 from the HC group. Peripheral blood samples, several clinical variables, and BMI were evaluated. Unlike 2-AG, AEA concentrations showed significant differences between groups (p < 0.001). Increased AEA was observed in the OB-ED and OB+ED compared with both HC and AN group, respectively. Likewise, AEA was differentially associated with emotional dysregulation, general psychopathology, food addiction, and BMI in all clinical groups. These results support the interaction between biological and clinical factors contributing to delineating vulnerability pathways in EWC that could help fit personalized therapeutic approaches.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

  • Cebrià Costa, Joan Pau
  • Serra Bardenys, Gemma
  • Querol, J
  • Cosín, M
  • Verde, Gaetano
  • Nuciforo, Paolo Giovanni
  • Arribas López, Joaquin Vicente
  • Peiro Sales, Sandra
  • Bernadó Morales, Cristina
  • Pascual Reguant, Laura
  • Gonzalez-Perez, Abel
  • Rodilla Benito, Verónica
Cromosomes; Marcadors pronòstics, Cromosomas; Marcadores de pronóstico, Chromosomes; Prognostic markers, Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenografts (PDXs) than those from other breast cancer subtypes. ChIP-seq revealed that H3K4ox is located primarily in heterochromatin, where it is involved in chromatin compaction. Knocking down LOXL2 reduces H3K4ox levels and causes chromatin decompaction, resulting in a sustained activation of the DNA damage response (DDR) and increased susceptibility to anticancer agents. This critical role that LOXL2 and oxidized H3 play in chromatin compaction and DDR suggests that functionally targeting LOXL2 could be a way to sensitize TNBC cells to conventional therapy., This work was supported by grants from Instituto de Salud Carlos III (ISCIII) FIS/FEDER (PI12/01250; CP08/00223; PI16/00253; and CB16/12/00449), MINECO (SAF2013-48849-C2-1-R) to SP, BFU2015-68354 to THS, Breast Cancer Research Foundation (BCRF-17-008) to JA, AGL2014-52395-C2-2-R to DA, Worldwide Cancer Research, Red Temática de Investigación Cooperativa en Cáncer (RD012/0036/005), Fundación Científica de la Asociación Española contra el Cáncer, and Fundació La Marató TV3. THS was supported by institutional funding (MINECO) through the Centres of Excellence Severo Ochoa award and the CERCA Programme of the Catalan Government, and SS-B, by a Fundació La Caixa fellowship. We thank La Caixa Foundation and Cellex Foundation for provide research facilities and equipment. GV has received funding from the MINECO (a “Juan de la Cierva Incorporation” fellowship; IJCI-2014-20723). SP was a recipient of a Miguel Servet contract (ISCIII/FIS), and AI, JPC-C, LP-G, and GS-B are supported by contracts from Worldwide Cancer Research, Fundació La Marató TV3, Fundació FERO, and a FI Fellowship from the Generalitat de Catalunya, respectively.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

  • Gorbatenko, Andrej
  • Søkilde, Rolf
  • Sorensen, Ester E.
  • Newie, Inga
  • Persson, Helena
  • Morancho Armisen, Beatriz
  • Arribas López, Joaquin Vicente
Mecanismes de la malaltia; Càncer de mama, Mecanismos de la enfermedad; Cáncer de mama, Disease Mechanisms; Breast Cancer, The HER2 oncogene and its truncated form p95HER2 play central roles in breast cancer. Here, we show that although HER2 and p95HER2 generally elicit qualitatively similar changes in miRNA profile in MCF-7 breast cancer cells, a subset of changes are distinct and p95HER2 shifts the miRNA profile towards the basal breast cancer subtype. High-throughput miRNA profiling was carried out 15, 36 and 60 h after HER2 or p95HER2 expression and central hits validated by RT-qPCR. miRNAs strongly regulated by p95HER2 yet not by HER2, included miR-221, miR-222, miR-503, miR-29a, miR-149, miR-196 and miR-361. Estrogen receptor-α (ESR1) expression was essentially ablated by p95HER2 expression, in a manner recapitulated by miR-221/-222 mimics. c-Myb family transcription factors MYB and MYBL1, but not MYBL2, were downregulated by p95HER2 and by miR-503 or miR-221/-222 mimics. MYBL1 3′UTR inhibition by miR-221/222 was lost by deletion of a single putative miR-221/222 binding sites. p95HER2 expression, or knockdown of either MYB protein, elicited upregulation of tissue inhibitor of matrix metalloprotease-2 (TIMP2). miR-221/222 and -503 mimics increased, and TIMP2 knockdown decreased, cell migration and invasion. A similar pathway was operational in T47D- and SKBr-3 cells. This work reveals important differences between HER2- and p95HER2- mediated miRNA changes in breast cancer cells, provides novel mechanistic insight into regulation of MYB family transcription factors by p95HER2, and points to a role for a miR-221/222– MYB family–TIMP2 axis in regulation of motility in breast cancer cells., This work was supported by the Danish Council for Independent Research (grants no. 12-126942 and 12-127290 to SFP), by the Hartmann foundation (SFP), Fondation Juchum (SFP), Kirsten og Freddy Johansens Fond (SFP), the Breast Cancer Research Foundation (BCRF-17-008) (JA), Instituto de Salud Carlos III (PI16/00253) (JA) and the Harboe foundation (SFP). Katrine Franklin Mark is gratefully acknowledged for excellent technical assistance. We are grateful to Pascal Pineau from Institut Pasteur, France for the MYBL1 3′UTR/psiCHECK2 construct.